BiotechTube

Pitolisant

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Hypersomnia

Conditions

Idiopathic Hypersomnia, Excessive Daytime Sleepiness

Trial Timeline

Aug 19, 2022 → Oct 1, 2025

NCT ID
NCT05458128

About Pitolisant

Pitolisant is a phase 3 stage product being developed by Harmony Biosciences for Idiopathic Hypersomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT05458128. Target conditions include Idiopathic Hypersomnia, Excessive Daytime Sleepiness.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT03433131Pre-clinicalCompleted
NCT07219485Phase 3Recruiting
NCT05581576ApprovedUNKNOWN
NCT05458128Phase 3Completed

Competing Products

20 competing products in Idiopathic Hypersomnia

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Rituximab + cyclosporineSun PharmaceuticalPhase 3
77
E5501EisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
77
Placebo + Avatrombopag tabletsEisaiPhase 2
52
PerampanelEisaiPre-clinical
23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77

Other Products from Harmony Biosciences

PitolisantApproved
80
Clemizole HCl + PlaceboPhase 3
72
PitolisantPhase 3
72
Open-label pitolisant + Double-blind placebo + Double-blind pitolisantPhase 3
72
Clemizole HCl + PlaceboPhase 3
72